Replies to post #2516 on Dynavax Technologies Corp (DVAX)

[mick]

Clover’s COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster • GlobeNewswire Inc. • 06/27/2022 10:04:28 AM
Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated,